Suppr超能文献

基于倾向得分匹配的长期中医药治疗对结直肠癌生存时间的影响:一项回顾性队列研究

The Effect of Long-Term Traditional Chinese Medicine Treatment on Survival Time of Colorectal Cancer Based on propensity Score Matching: A Retrospective Cohort Study.

作者信息

Wang Yuli, Liu Ping, Fang Yuan, Tian Jianhui, Li Shufang, Xu Jing, Zhao Fanchen, Yin Xiaoling, Zhang Qiang, Li Yan

机构信息

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Ganquan Street Community Hospital of Shanghai Putuo District, Shanghai, China.

出版信息

Evid Based Complement Alternat Med. 2020 Jan 31;2020:7023420. doi: 10.1155/2020/7023420. eCollection 2020.

Abstract

OBJECTIVE

To explore the effect of long-term traditional Chinese medicine (TCM) treatment on survival time of colorectal cancer (hereinafter referred to as CRC).

METHODS

Our clinical study included patients who were diagnosed with CRC clinically or pathologically. Patients were divided into TCM treatment group and control group according to whether the modified Anti-cancer Decoction II Formula was applied for more than six months. Propensity score matching (hereinafter referred to as PSM) was used to further balance the covariates between groups. One-year to six-year progression-free survival rates of the two groups and the median progression-free survival (mPFS), median overall survival (mOS) of the two groups before and after PSM were calculated respectively. Furthermore, 15 factors that may affect the mPFS in CRC were included in COX multivariate regression analysis to explore the prognostic factors related to CRC as well as to analyze the risk ratio of different subgroups.

RESULTS

A total of 529 CRC patients were included in our study, 285 patients were in the TCM treatment group and 244 patients were in the control group. Before PSM, the mPFS and mOS in the TCM treatment group were 68 months and 75 months respectively, while mPFS and mOS in the control group were 40 months and 65 months respectively. After PSM, mPFS and mOS in the TCM treatment group were both 75 months, while mPFS and mOS in the control group were 28 months and 44 months respectively. One-year to six-year progression-free survival rates were 94.0%, 76.1%, 64.7%, 57.9%, 52.0%, 44.1% respectively in the TCM treatment group, and 78.6%, 61.4%, 51.7%, 40.8%, 33.0%, 29.1% respectively in the control group ( < 0.01) COX multivariate regression analysis indicated that surgery, chemotherapy and taking Chinese herbal decoction were protective factors for CRC recurrence and metastasis, while combining with intestinal obstruction, drinking history and family history were independent factors for CRC recurrence and metastasis. The results of subgroup analysis showed that the decoction of TCM could reduce the risk of recurrence and metastasis in each subgroup ( < 0.01) COX multivariate regression analysis indicated that surgery, chemotherapy and taking Chinese herbal decoction were protective factors for CRC recurrence and metastasis, while combining with intestinal obstruction, drinking history and family history were independent factors for CRC recurrence and metastasis. The results of subgroup analysis showed that the decoction of TCM could reduce the risk of recurrence and metastasis in each subgroup (.

CONCLUSIONS

Long-term TCM treatment by the usage of the modified Anti-cancer Decoction II Formula not only has a positive effect on the survival time of CRC patients, but also helps reduce the risk of recurrence and metastasis of CRC, which can be flexibly applied in the whole process of CRC treatment.

摘要

目的

探讨长期中医药治疗对结直肠癌(以下简称CRC)患者生存时间的影响。

方法

本临床研究纳入临床或病理诊断为CRC的患者。根据是否应用改良抗癌二号方超过6个月,将患者分为中医药治疗组和对照组。采用倾向得分匹配法(以下简称PSM)进一步平衡组间协变量。分别计算两组PSM前后1年至6年无进展生存率以及两组的中位无进展生存期(mPFS)、中位总生存期(mOS)。此外,将可能影响CRC患者mPFS的15个因素纳入COX多因素回归分析,以探讨CRC的预后因素,并分析不同亚组的风险比。

结果

本研究共纳入529例CRC患者,其中中医药治疗组285例,对照组244例。PSM前,中医药治疗组的mPFS和mOS分别为68个月和75个月,而对照组的mPFS和mOS分别为40个月和65个月。PSM后,中医药治疗组的mPFS和mOS均为75个月,而对照组的mPFS和mOS分别为28个月和44个月。中医药治疗组1年至6年无进展生存率分别为94.0%、76.1%、64.7%、57.9%、52.0%、44.1%,对照组分别为78.6%、61.4%、51.7%、40.8%、33.0%、29.1%(<0.01)。COX多因素回归分析表明,手术、化疗及服用中药汤剂是CRC复发转移的保护因素,而合并肠梗阻、饮酒史及家族史是CRC复发转移的独立因素。亚组分析结果显示,中药汤剂可降低各亚组复发转移风险(<0.01)。COX多因素回归分析表明,手术、化疗及服用中药汤剂是CRC复发转移的保护因素,而合并肠梗阻、饮酒史及家族史是CRC复发转移的独立因素。亚组分析结果显示,中药汤剂可降低各亚组复发转移风险(。

结论

应用改良抗癌二号方进行长期中医药治疗不仅对CRC患者的生存时间有积极影响,而且有助于降低CRC复发转移风险,可在CRC治疗全程灵活应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c81/7013320/60bf748e8d96/ECAM2020-7023420.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验